Hydrochloride salt Valnemulin, semisynthetic antibiotic; derivative of pleuromutilin. Antibacterial.
Valnemulin Hydrochloride is a semisynthetic antibiotic; derivative of pleuromutilin. Antibacterial.
Valnemulin hydrochloride is the salt prepared from valnemulin taking advantage of the basic amino group which protonates and readily forms the salt in hydrochloric acid solutions. The hydrochloride is the preferred formulation for pharmaceutical applications. Valnemulin is a broad spectrum antibiotic used to control gastrointestinal infections in animals, and shows no cross resistance to other antibiotic classes. Like all the pleuromutilins, valnemulin inhibits protein synthesis by binding to domain V of 23S RNA.
Valnemulin Hydrochloride inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome. More specifically, it binds to the peptidyl transferase center of the ribosome and interferes with the transfer of amino acids to growing polypeptide chains, leading to the inhibition of protein synthesis and bacterial death.
Valnemulin hydrochloride (10 mg/kg in non-salt form; Oral administration; 10 days) has a control effect in experimental infection of calves with Mycoplasma bovis, and can effectively eliminate Mycobacterium bovis in the lungs [1].
Valnemulin hydrochloride (20-35 ppm; Feed administration; 21 days) effectively reduces the mortality of epidemic rabbit enteropathy, and has no adverse effect on the growth performance of rabbits [2].
| Animal Model: | Mycoplasma bovis infection treated male calves aged 10-35 days[1] |
| Dosage: | 10 mg/kg in non-salt form |
| Administration: | Oral administration (p.o.); 10 days |
| Result: | Resulted in a rapid diminution of clinical signs, restoration of appetite and reversal of weight loss.
Effectively reduced the isolation of Pasteurella multocida from the calves, lungs.
|
| Animal Model: | Hycole strain rabbits aged 33-37 days with epizootic rabbit enteropathy[2] |
| Dosage: | 20 or 35 parts per million (ppm) |
| Administration: | Feed administration; 21 days |
| Result: | Reduced rabbit mortality. Epizootic rabbit enteropathy mortality was 23% in untreated rabbits and 11% and 7.6% in rabbits treated with 20 and 35 ppm doses, respectively.
Had no detrimental effects on appetite, weight gain or feed conversion rate.
|
